Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Common Equity (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Common Equity for 6 consecutive years, with $107.5 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 26.32% to $107.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $107.5 million through Dec 2025, down 26.32% year-over-year, with the annual reading at $107.5 million for FY2025, 26.32% down from the prior year.
  • Common Equity for Q4 2025 was $107.5 million at Lexicon Pharmaceuticals, down from $120.2 million in the prior quarter.
  • The five-year high for Common Equity was $288.9 million in Q1 2024, with the low at $88.0 million in Q1 2023.
  • Average Common Equity over 3 years is $153.4 million, with a median of $134.5 million recorded in 2023.
  • The sharpest move saw Common Equity surged 228.09% in 2024, then crashed 57.41% in 2025.
  • Over 3 years, Common Equity stood at $93.1 million in 2023, then skyrocketed by 56.75% to $146.0 million in 2024, then dropped by 26.32% to $107.5 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $107.5 million, $120.2 million, and $129.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.